Century Therapeutics, Inc. (IPSC) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-12
What protects it: the moat
It relies on its Allo-Evasion™ technology and the self-renewing nature of iPSCs to prevent immune rejection and ensure scalability.
Management claims that focusing on induced pluripotent stem cells allows for virtually unlimited genetic editing and consistent reproducibility.
The Allo-Evasion™ technology is intended to prevent the host immune system from rejecting the cell products, which would allow for the persistence and re-dosing of therapy.
What growth costs
It must spend on preclinical studies, clinical trials, and the development of complex manufacturing processes.
The company must fund the advancement of product candidates through expensive preclinical and clinical stages to obtain marketing approval.
It also invests in cutting-edge manufacturing capabilities to drive scale advantages and minimize supply risk.
What could damage it
The termination of license agreements with FCDI would strip it of rights to key platform components.
The company's allogeneic cell therapy platforms depend on specific licensed components. If these agreements are terminated, it would lose the legal right to use the core technology required to develop its products.
About Century Therapeutics, Inc.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.